Cubist sees antibiotic Cubicin '07 net rev up 35 pct to 45 pct

April 18 (Reuters) - Cubist Pharmaceuticals Inc. (CBST.O) said it expects 2007 net revenue growth for its antibiotic Cubicin to increase by 35 percent to 45 percent.

In a conference call with analysts, the biopharmaceutical company reiterated its previous outlook of U.S. net product revenue of $255 million to $275 million for the year.

Net international revenue for 2007 is still expected in the range of $5 million to $10 million. (Reporting by Neha Pathania in Bangalore)